

David B Solit

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5561227/david-b-solit-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

318
papers

40,612
citations

107
h-index

198
g-index

353
ext. papers

50,198
ext. citations

13.3
avg, IF

7.19
L-index

#	Paper	IF	Citations
318	BRAF Mutations: The Discovery of Allele- and Lineage-Specific Differences.. <i>Cancer Research</i> , 2022 , 82, 12-14	10.1	
317	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.. <i>Cell</i> , 2022 , 185, 563-575.e11	56.2	11
316	Defining and Targeting Esophagogastric Cancer Genomic Subsets With Patient-Derived Xenografts.. <i>JCO Precision Oncology</i> , 2022 , 6, e2100242	3.6	0
315	Anatomic position determines oncogenic specificity in melanoma.. <i>Nature</i> , 2022 ,	50.4	3
314	AKT mutant allele-specific activation dictates pharmacologic sensitivities.. <i>Nature Communications</i> , 2022 , 13, 2111	17.4	2
313	The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas. <i>Clinical Cancer Research</i> , 2021 , 27, 1516-1525	12.9	2
312	AKT1 E17K Inhibits Cancer Cell Migration by Abrogating E-Catenin Signaling. <i>Molecular Cancer Research</i> , 2021 , 19, 573-584	6.6	6
311	The context-specific role of germline pathogenicity in tumorigenesis. <i>Nature Genetics</i> , 2021 , 53, 1577-1585	35.3	6
310	HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway. <i>Nature Communications</i> , 2021 , 12, 6667	17.4	4
309	Molecular and phenotypic profiling of colorectal cancer patients in West Africa reveals biological insights. <i>Nature Communications</i> , 2021 , 12, 6821	17.4	2
308	Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors. <i>Clinical Cancer Research</i> , 2021 ,	12.9	6
307	Genomic Profiling Aids Classification of Diagnostically Challenging Uterine Mesenchymal Tumors With Myomelanocytic Differentiation. <i>American Journal of Surgical Pathology</i> , 2021 , 45, 77-92	6.7	9
306	OncoTree: A Cancer Classification System for Precision Oncology. <i>JCO Clinical Cancer Informatics</i> , 2021 , 5, 221-230	5.2	11
305	Clinical cancer genomic profiling. <i>Nature Reviews Genetics</i> , 2021 , 22, 483-501	30.1	15
304	Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial. <i>PLoS ONE</i> , 2021 , 16, e0248097	3.7	3
303	Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways. <i>Clinical Cancer Research</i> , 2021 , 27, 3491-3498	12.9	1
302	Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. <i>Genome Medicine</i> , 2021 , 13, 96	14.4	8

301	Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non-Muscle-Invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 4599-4609	12.9	4
300	Molecular classification and diagnostics of upper urinary tract urothelial carcinoma. <i>Cancer Cell</i> , 2021 , 39, 793-809.e8	24.3	13
299	Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. <i>Nature Communications</i> , 2021 , 12, 3770	17.4	10
298	Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer. <i>JAMA Network Open</i> , 2021 , 4, e2114753	10.4	4
297	Association of RAS Mutation Location and Oncologic Outcomes After Resection of Colorectal Liver Metastases. <i>Annals of Surgical Oncology</i> , 2021 , 28, 817-825	3.1	5
296	Lessons from the Study of Exceptional Responders. <i>Cancer Cell</i> , 2021 , 39, 11-13	24.3	0
295	Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 1997-2010	12.9	2
294	Re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2020.07.016 . <i>European Urology</i> , 2021 , 79, e56-e57	10.2	
293	Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 2011-2022	12.9	6
292	The association between tumor mutational burden and prognosis is dependent on treatment context. <i>Nature Genetics</i> , 2021 , 53, 11-15	36.3	38
291	Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis. <i>Nature Communications</i> , 2021 , 12, 338	17.4	21
290	Prevalence and Characterization of Biallelic and Monoallelic and Variant Carriers From a Pan-Cancer Patient Population. <i>JCO Precision Oncology</i> , 2021 , 5,	3.6	3
289	A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma. <i>JAMA Surgery</i> , 2021 , 156, e205601	5.4	16
288	Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non-Small Cell Lung or Colorectal Cancer. <i>JAMA Network Open</i> , 2021 , 4, e2117547	10.4	2
287	Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy. <i>Cancer Cell</i> , 2021 , 39, 1375-1387.e6	24.3	16
286	A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	12
285	TNFR2/14-3-3 β signaling complex instructs macrophage plasticity in inflammation and autoimmunity. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	6
284	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2698-2709	2.2	16

283	() Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary Tract.. <i>Bladder Cancer</i> , 2021 , 7, 395-400	1	1
282	Novel Mouse Models of Bladder Cancer Identify a Prognostic Signature Associated with Risk of Disease Progression. <i>Cancer Research</i> , 2021 , 81, 5161-5175	10.1	1
281	Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma. <i>Hepatology</i> , 2021 , 74, 1429-1444	11.2	14
280	Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study. <i>JCO Precision Oncology</i> , 2021 , 5,	3.6	2
279	Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma. <i>British Journal of Cancer</i> , 2021 , 124, 1214-1221	8.7	4
278	Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas. <i>Clinical Cancer Research</i> , 2021 , 27, 2226-2235	12.9	6
277	Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	4
276	Aggressive Hematopoietic Malignancy Characterized by Biallelic Loss of. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	0
275	First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , 2020 , 21, 821-831	21.7	104
274	Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 3230-3238	12.9	49
273	Protein-altering germline mutations implicate novel genes related to lung cancer development. <i>Nature Communications</i> , 2020 , 11, 2220	17.4	6
272	MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by Fusions. <i>Clinical Cancer Research</i> , 2020 , 26, 2932-2945	12.9	14
271	Fragment Size Analysis May Distinguish Clonal Hematopoiesis from Tumor-Derived Mutations in Cell-Free DNA. <i>Clinical Chemistry</i> , 2020 , 66, 616-618	5.5	14
270	Leveraging Systematic Functional Analysis to Benchmark a Framework Distinguishes Driver from Passenger MEK Mutants in Cancer. <i>Cancer Research</i> , 2020 , 80, 4233-4243	10.1	9
269	Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings. <i>Cancer</i> , 2020 , 126, 1995-2002	6.4	9
268	Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer. <i>Oncologist</i> , 2020 , 25, e68-e74	5.7	5
267	Efficacy and Determinants of Response to HER Kinase Inhibition in -Mutant Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2020 , 10, 198-213	24.4	41
266	Coaltered and Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 1077-1085	12.9	37

265	Alterations in and promote clinical resistance to alpelisib plus aromatase inhibitors. <i>Nature Cancer</i> , 2020 , 1, 382-393	15.4	49
264	Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts. <i>Nature Communications</i> , 2020 , 11, 1975	17.4	17
263	Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics. <i>European Urology</i> , 2020 , 78, 671-679	10.2	37
262	Interplay between Chromosomal Alterations and Gene Mutations Shapes the Evolutionary Trajectory of Clonal Hematopoiesis. <i>Blood</i> , 2020 , 136, 29-30	2.2	
261	Overcoming Adaptive Resistance to KRAS Inhibitors Through Vertical Pathway Targeting. <i>Clinical Cancer Research</i> , 2020 , 26, 1538-1540	12.9	13
260	Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor. <i>Journal of Clinical Investigation</i> , 2020 , 130, 6668-6676	15.9	15
259	Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care. <i>JAMA Oncology</i> , 2020 , 6, 84-91	13.4	33
258	Cancer Susceptibility Mutations in Patients With Urothelial Malignancies. <i>Journal of Clinical Oncology</i> , 2020 , 38, 406-414	2.2	31
257	Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver. <i>Cancer</i> , 2020 , 126, 4126-4135	6.4	0
256	Inverted urothelial papilloma and urothelial carcinoma with inverted growth are histologically and molecularly distinct entities. <i>Journal of Pathology</i> , 2020 , 250, 464-465	9.4	4
255	Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. <i>Breast Cancer Research</i> , 2020 , 22, 120	8.3	22
254	Accelerating precision medicine in metastatic prostate cancer. <i>Nature Cancer</i> , 2020 , 1, 1041-1053	15.4	18
253	A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma. <i>Cancer</i> , 2020 , 126, 4532-4544	6.4	2
252	Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial. <i>Gynecologic Oncology</i> , 2020 , 159, 150-156	4.9	8
251	Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2020 , 78, 907-915	10.2	9
250	RAS/MAPK Pathway Driver Alterations Are Significantly Associated With Oncogenic KIT Mutations in Germ-cell Tumors. <i>Urology</i> , 2020 , 144, 111-116	1.6	2
249	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. <i>Nature Genetics</i> , 2020 , 52, 1219-1226	13.6	103
248	Intracellular Signaling 2020 , 24-46.e12		

247	Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing. <i>Clinical Cancer Research</i> , 2020 , 26, 3881-3888	12.9	16
246	Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations. <i>JCO Precision Oncology</i> , 2020 , 4, 355-366	3.6	35
245	HER2-Mediated Internalization of Cytotoxic Agents in Amplified or Mutant Lung Cancers. <i>Cancer Discovery</i> , 2020 , 10, 674-687	24.4	66
244	Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers. <i>Cancer</i> , 2019 , 125, 4380-4387	6.4	26
243	Analysis of Tumor Genomic Pathway Alterations Using Broad-Panel Next-Generation Sequencing in Surgically Resected Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2019 , 25, 7475-7484	12.9	14
242	PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer. <i>Npj Breast Cancer</i> , 2019 , 5, 31	7.8	8
241	Precision Oncology: Three Small Steps Forward. <i>Cancer Cell</i> , 2019 , 35, 825-826	24.3	6
240	Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. <i>European Journal of Cancer</i> , 2019 , 114, 128-136	7.5	7
239	Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. <i>Annals of Oncology</i> , 2019 , 30, 597-603	10.3	74
238	Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder. <i>Journal of Pathology</i> , 2019 , 248, 260-265	9.4	20
237	Efficacy of Combined VEGFR1-3, PDGFR α and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 3811-3817	12.9	5
236	Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. <i>Journal of Clinical Oncology</i> , 2019 , 37, 286-295	2.2	203
235	Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer. <i>Gastric Cancer</i> , 2019 , 22, 355-362	7.6	9
234	Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 977-988	12.9	57
233	Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 6160-6169	12.9	45
232	Tumour lineage shapes BRCA-mediated phenotypes. <i>Nature</i> , 2019 , 571, 576-579	50.4	170
231	Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. <i>Clinical Cancer Research</i> , 2019 , 25, 5537-5547	12.9	48
230	Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. <i>Journal of Clinical Investigation</i> , 2019 , 129, 4276-4289	15.9	64

229	Annotation of Somatic Genomic Variants in Hematologic Diseases Using OncoKB, a Precision Oncology Knowledgebase. <i>Blood</i> , 2019 , 134, 2148-2148	2.2	0
228	"Primary" and "secondary" muscle-invasive bladder cancer is more than just a surrogate for molecular subtypes.. <i>Translational Cancer Research</i> , 2019 , 8, S642-S644	0.3	1
227	Real-World Outcomes of an Automated Physician Support System for Genome-Driven Oncology. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	3
226	Genomic Characterization of -Driven Biliary Cancer and a Case of Response to Ado-Trastuzumab Emtansine. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	10
225	Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib. <i>Clinical Cancer Research</i> , 2019 , 25, 7381-7387	12.9	9
224	Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. <i>Nature Medicine</i> , 2019 , 25, 1839-1842	50.5	55
223	PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology: Concordance Among 3 Commonly Used and Commercially Available Antibodies. <i>American Journal of Surgical Pathology</i> , 2019 , 43, 920-927	6.7	30
222	High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. <i>Nature Medicine</i> , 2019 , 25, 1928-1937	50.5	263
221	Harnessing Clinical Sequencing Data for Survival Stratification of Patients with Metastatic Lung Adenocarcinomas. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	13
220	Lobular Carcinomas Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma. <i>Clinical Cancer Research</i> , 2019 , 25, 674-686	12.9	31
219	Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. <i>JAMA Oncology</i> , 2019 , 5, 471-478	13.4	257
218	Regional differences in gallbladder cancer pathogenesis: Insights from a multi-institutional comparison of tumor mutations. <i>Cancer</i> , 2019 , 125, 575-585	6.4	23
217	and Amplifications Determine Response to HER2 Inhibition in -Amplified Esophagogastric Cancer. <i>Cancer Discovery</i> , 2019 , 9, 199-209	24.4	79
216	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019 , 51, 202-206	36.3	1435
215	Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. <i>Clinical Cancer Research</i> , 2019 , 25, 967-976	12.9	94
214	Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies. <i>Clinical Cancer Research</i> , 2019 , 25, 2116-2126	12.9	219
213	Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. <i>European Urology</i> , 2019 , 75, 231-239	10.2	53
212	Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma. <i>European Urology Focus</i> , 2019 , 5, 201-204	5.1	18

211	Genomic Profile of Urothelial Carcinoma of the Upper Tract from Ureteroscopic Biopsy: Feasibility and Validation Using Matched Radical Nephroureterectomy Specimens. <i>European Urology Focus</i> , 2019 , 5, 365-368	5.1	9
210	Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties. <i>Cancer Discovery</i> , 2018 , 8, 648-661	24.4	57
209	Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer. <i>Cell</i> , 2018 , 173, 515-528.e17	56.2	310
208	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. <i>Nature</i> , 2018 , 554, 189-194	50.4	388
207	Accelerating Discovery of Functional Mutant Alleles in Cancer. <i>Cancer Discovery</i> , 2018 , 8, 174-183	24.4	162
206	Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. <i>Cancer Cell</i> , 2018 , 33, 125-136.e3	24.3	338
205	Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma. <i>Human Pathology</i> , 2018 , 77, 63-69	3.7	18
204	Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance. <i>Clinical Cancer Research</i> , 2018 , 24, 3108-3118	12.9	123
203	Effects of Co-occurring Genomic Alterations on Outcomes in Patients with -Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 334-340	12.9	173
202	Opportunities and Challenges in Genomic Sequencing for Precision Cancer Care. <i>Annals of Internal Medicine</i> , 2018 , 168, 221-222	8	4
201	Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 5939-5947	12.9	60
200	Genome doubling shapes the evolution and prognosis of advanced cancers. <i>Nature Genetics</i> , 2018 , 50, 1189-1195	36.3	208
199	Clinical tumour sequencing for precision oncology: time for a universal strategy. <i>Nature Reviews Cancer</i> , 2018 , 18, 527-528	31.3	20
198	Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2018 , 25, 2027-2033	3.1	12
197	Rates of Alterations across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an -Amplified Acral Melanoma. <i>Clinical Cancer Research</i> , 2018 , 24, 5815-5819	12.9	13
196	Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors. <i>JAMA Oncology</i> , 2018 , 4, 1589-1593	13.4	91
195	Activating Mutations in CSF1R and Additional Receptor Tyrosine Kinases in Sporadic and Familial Histiocytic Neoplasms. <i>Blood</i> , 2018 , 132, 49-49	2.2	5
194	Frequency of actionable cancer predisposing germline mutations in patients with lung cancers.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1504-1504	2.2	2

193	A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2502-2502	2.2	23
192	Microsatellite instability in prostate cancer and response to immune checkpoint blockade.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 5020-5020	2.2	14
191	Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. <i>Clinical Cancer Research</i> , 2018 , 24, 1965-1973	12.9	51
190	Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. <i>Science</i> , 2018 , 359, 582-587	33.3	500
189	Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. <i>Cancer Discovery</i> , 2018 , 8, 49-58	24.4	180
188	Genomic Characterization of Upper-Tract Urothelial Carcinoma in Patients With Lynch Syndrome. <i>JCO Precision Oncology</i> , 2018 , 2018,	3.6	15
187	Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1685-1694	23.4	274
186	Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2532-2537	2.2	217
185	Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. <i>Journal of Clinical Oncology</i> , 2018 , 36, 633-641	2.2	730
184	Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1949-1956	2.2	72
183	Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). <i>Science Signaling</i> , 2018 , 11,	8.8	32
182	Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer. <i>Cancer Cell</i> , 2018 , 34, 852-862.e14.3	4.3	50
181	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. <i>Cancer Cell</i> , 2018 , 34, 427-438.e16.3	24.6	339
180	Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation. <i>New England Journal of Medicine</i> , 2018 , 378, 1945-1947	59.2	35
179	Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention. <i>Clinical Cancer Research</i> , 2018 , 24, 4154-4161	12.9	182
178	A Phase Ib Study of Alpelisib (BYL719), a PI3K α -Specific Inhibitor, with Letrozole in ER+/HER2-Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 26-34	12.9	204
177	3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets. <i>Genome Medicine</i> , 2017 , 9, 4	14.4	117
176	DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. <i>Clinical Cancer Research</i> , 2017 , 23, 3610-3618	12.9	143

175	ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer. <i>Cancer Research</i> , 2017 , 77, 1035-1046	10.1	12
174	Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy. <i>Clinical Cancer Research</i> , 2017 , 23, 3168-3180	24.4	51
173	An Acquired Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. <i>Cancer Discovery</i> , 2017 , 7, 575-585	24.4	66
172	Gene Signature Associated with Upregulation of the Wnt/ β Catenin Signaling Pathway Predicts Tumor Response to Transarterial Embolization. <i>Journal of Vascular and Interventional Radiology</i> , 2017 , 28, 349-355.e1	2.4	11
171	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017 , 23, 703-713	50.5	1638
170	AACR Project GENIE: Powering Precision Medicine through an International Consortium. <i>Cancer Discovery</i> , 2017 , 7, 818-831	24.4	629
169	Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. <i>Cancer Discovery</i> , 2017 , 7, 596-609	24.4	317
168	Next-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guérin. <i>Cancer Cytopathology</i> , 2017 , 125, 416-426	3.9	20
167	Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. <i>Annals of Oncology</i> , 2017 , 28, 512-518	10.3	125
166	Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. <i>Cancer Research</i> , 2017 , 77, 6513-6523	10.1	43
165	Clinical and molecular characterization of patients with cancer of unknown primary in the modern era. <i>Annals of Oncology</i> , 2017 , 28, 3015-3021	10.3	52
164	A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer. <i>Breast Cancer Research</i> , 2017 , 19, 89	8.3	32
163	Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets. <i>European Urology</i> , 2017 , 72, 952-959	10.2	168
162	Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. <i>JCO Precision Oncology</i> , 2017 , 2017,	3.6	151
161	AKT Inhibition in Solid Tumors With AKT1 Mutations. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2251-2259	2.2	184
160	OncoKB: A Precision Oncology Knowledge Base. <i>JCO Precision Oncology</i> , 2017 , 2017,	3.6	699
159	Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases. <i>Oncotarget</i> , 2017 , 8, 66117-66127	3.3	55
158	Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma. <i>JCO Precision Oncology</i> , 2017 , 1,	3.6	11

157	Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 318, 825-835	27.4	235
156	Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. <i>Clinical Cancer Research</i> , 2017 , 23, 6094-6100	12.9	107
155	Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. <i>Nature</i> , 2017 , 548, 234-238	50.4	259
154	Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. <i>Cell Stem Cell</i> , 2017 , 21, 374-382.e4	18	339
153	Oncologist use and perception of large panel next-generation tumor sequencing. <i>Annals of Oncology</i> , 2017 , 28, 2298-2304	10.3	24
152	Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases. <i>Cancer</i> , 2017 , 123, 568-575	6.4	28
151	The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform. <i>JAMA Oncology</i> , 2017 , 3, 244-255	13.4	141
150	Mismatch repair (MMR) detection in urothelial carcinoma (UC) and correlation with immune checkpoint blockade (ICB) response.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4511-4511	2.2	19
149	DNA damage response (DDR) gene mutations (mut), mut load, and sensitivity to chemotherapy plus immune checkpoint blockade in urothelial cancer (UC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 300-300	2.2	5
148	PI3K pathway mutations are associated with longer time to local progression after radioembolization of colorectal liver metastases. <i>Oncotarget</i> , 2017 , 8, 23529-23538	3.3	23
147	Local recurrences at the anastomotic area are clonally related to the primary tumor in sporadic colorectal carcinoma. <i>Oncotarget</i> , 2017 , 8, 42487-42494	3.3	6
146	JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors. <i>Science Signaling</i> , 2016 , 9, ra33	8.8	41
145	Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2016 , 2, 165-202 ¹		22
144	Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, e81-90	3.3	4
143	Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center. <i>Pediatric Blood and Cancer</i> , 2016 , 63, 1368-74	3	28
142	Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. <i>JAMA Oncology</i> , 2016 , 2, 104-11	13.4	198
141	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. <i>Cancer Discovery</i> , 2016 , 6, 154-654.4	4.4	269
140	Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. <i>Nature Genetics</i> , 2016 , 48, 356-8	36.3	111

139	Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2016 , 195, 1684-1689	2.5	27
138	Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF. <i>Molecular Cancer Research</i> , 2016 , 14, 296-301	6.6	34
137	Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. <i>Nature Biotechnology</i> , 2016 , 34, 155-63	44.5	465
136	Mutational Analysis of Clonal Hematopoiesis in Solid Tumor Patients Illustrates the Critical Role of Systemic Anti-Cancer Therapies in the Evolution of Somatic Leukemia Disease Alleles. <i>Blood</i> , 2016 , 128, 37-37	2.2	2
135	Prognostic significance of DNA damage repair (DDR) mutations in patients with urothelial carcinoma (UC) and associations with tumor infiltrating lymphocytes (TILs).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4538-4538	2.2	4
134	Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression. <i>Journal of Pathology</i> , 2016 , 238, 508-18	9.4	80
133	Reply to M.P. Decatris et al. <i>Journal of Clinical Oncology</i> , 2016 , 34, 887	2.2	
132	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2016 , 375, 443-53	59.2	791
131	Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2141-7	2.2	170
130	Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition. <i>European Urology</i> , 2016 , 70, 771-775	10.2	42
129	Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 4623-33	12.9	114
128	Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4000-4007	2.2	110
127	Genomic characterization of response to chemoradiation in urothelial bladder cancer. <i>Cancer</i> , 2016 , 122, 3715-3723	6.4	37
126	A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases. <i>Oncologist</i> , 2015 , 20, 789-97	5.7	48
125	MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking. <i>Clinical Cancer Research</i> , 2015 , 21, 1935-43	12.9	95
124	Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4099-105	2.2	75
123	Genomic Characterization of Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2015 , 68, 970-7	10.2	147
122	Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. <i>Drug Discovery Today</i> , 2015 , 20, 1422-8	8.8	117

121	BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. <i>Cancer Cell</i> , 2015 , 28, 370-83	24.3	266
120	Convergent loss of PTEN leads to clinical resistance to a PI(3)K inhibitor. <i>Nature</i> , 2015 , 518, 240-4	50.4	366
119	Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder. <i>European Urology</i> , 2015 , 67, 198-201	10.2	105
118	RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. <i>Cancer</i> , 2015 , 121, 1195-203	6.4	120
117	Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion. <i>PLoS ONE</i> , 2015 , 10, e0126633	3.7	27
116	Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells. <i>ELife</i> , 2015 , 4,	8.9	65
115	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. <i>Blood</i> , 2015 , 126, 481-481	2.2	
114	Next-Generation Sequencing of Matched Normal Blood Identifies Clonal Hematopoiesis in a Significant Subset of Solid Tumor Patients without Hematologic Malignancies. <i>Blood</i> , 2015 , 126, 2447-2477	2.2	
113	Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies. <i>Cancer Discovery</i> , 2014 , 4, 538-45	24.4	62
112	Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors. <i>Clinical Cancer Research</i> , 2014 , 20, 3712-20	12.9	75
111	Towards a unified model of RAF inhibitor resistance. <i>Cancer Discovery</i> , 2014 , 4, 27-30	24.4	33
110	Realizing the potential of plasma genotyping in an age of genotype-directed therapies. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	38
109	Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2014 , 13, 207-12	3.8	29
108	BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. <i>Cancer</i> , 2014 , 120, 2316-24	6.4	136
107	Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouraged. <i>Cancer Cell</i> , 2014 , 26, 603-4	24.3	42
106	Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, E748-57	11.5	76
105	Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. <i>Cancer Discovery</i> , 2014 , 4, 1140-53	24.4	361
104	Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. <i>Genome Biology</i> , 2014 , 15, 454	18.3	224

103	Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy. <i>Cancer Discovery</i> , 2014 , 4, 1014-21	24.4	98
102	Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. <i>Cancer Research</i> , 2014 , 74, 2340-50	10.1	204
101	Mutant N-RAS protects colorectal cancer cells from stress-induced apoptosis and contributes to cancer development and progression. <i>Cancer Discovery</i> , 2013 , 3, 294-307	24.4	50
100	ERK pathway inhibitors: how low should we go?. <i>Cancer Discovery</i> , 2013 , 3, 719-21	24.4	39
99	Tumor adaptation and resistance to RAF inhibitors. <i>Nature Medicine</i> , 2013 , 19, 1401-9	50.5	419
98	Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3133-40	2.2	226
97	Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. <i>Nature Genetics</i> , 2013 , 45, 253-61	36.3	231
96	BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. <i>Cancer</i> , 2013 , 119, 548-554	6.4	135
95	Perturbation biology: inferring signaling networks in cellular systems. <i>PLoS Computational Biology</i> , 2013 , 9, e1003290	5	98
94	Pilot study of 68Ga-DOTA-F(ab) ₂ -trastuzumab in patients with breast cancer. <i>Nuclear Medicine Communications</i> , 2013 , 34, 1157-65	1.6	48
93	Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. <i>Clinical Cancer Research</i> , 2013 , 19, 2257-64	12.9	108
92	Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells. <i>Cancer Research</i> , 2013 , 73, 1156-67	10.1	68
91	Phase II study of everolimus in metastatic urothelial cancer. <i>BJU International</i> , 2013 , 112, 462-70	5.6	133
90	Progression of RAS-mutant leukemia during RAF inhibitor treatment. <i>New England Journal of Medicine</i> , 2012 , 367, 2316-21	59.2	185
89	Genome sequencing identifies a basis for everolimus sensitivity. <i>Science</i> , 2012 , 338, 221	33.3	546
88	Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2012 , 11, 101-11	3.8	58
87	Monitoring the Induction of Heat Shock Factor 1/Heat Shock Protein 70 Expression following 17-Allylamino-Demethoxygeldanamycin Treatment by Positron Emission Tomography and Optical Reporter Gene Imaging. <i>Molecular Imaging</i> , 2012 , 11, 7290.2011.00028	3.7	8
86	Will Hsp90 inhibitors prove effective in BRAF-mutant melanomas?. <i>Clinical Cancer Research</i> , 2012 , 18, 2420-2	12.9	14

85	A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors. <i>Cancer</i> , 2012 , 118, 4795-800	6.4	50
84	Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. <i>Nature</i> , 2012 , 486, 532-6	50.4	1327
83	Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. <i>Nature</i> , 2012 , 487, 500-4	50.4	1308
82	A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 1089-97	3.5	27
81	Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 70, 201-5	3.5	4
80	Comparative genomic analysis of primary versus metastatic colorectal carcinomas. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2956-62	2.2	225
79	RAF/MEK dependence of KRAS-mutant pancreatic ductal adenocarcinomas. <i>Cancer Discovery</i> , 2012 , 2, 666-9	24.4	10
78	Genomic complexity and AKT dependence in serous ovarian cancer. <i>Cancer Discovery</i> , 2012 , 2, 56-67	24.4	89
77	BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. <i>Cancer Discovery</i> , 2012 , 2, 791-7	24.4	160
76	Monitoring the induction of heat shock factor 1/heat shock protein 70 expression following 17-allylamino-demethoxygeldanamycin treatment by positron emission tomography and optical reporter gene imaging. <i>Molecular Imaging</i> , 2012 , 11, 67-76	3.7	7
75	Resistance to BRAF inhibition in melanomas. <i>New England Journal of Medicine</i> , 2011 , 364, 772-4	59.2	189
74	Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. <i>Nature Genetics</i> , 2011 , 43, 964-968	36.3	242
73	Resistance to MEK inhibitors: should we co-target upstream?. <i>Science Signaling</i> , 2011 , 4, pe16	8.8	98
72	RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). <i>Nature</i> , 2011 , 480, 387-90	50.4	1107
71	The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?. <i>Current Oncology Reports</i> , 2011 , 13, 479-87	6.3	29
70	Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma. <i>Journal of Pathology</i> , 2011 , 224, 270-9	9.4	62
69	Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET inhibition. <i>Clinical Cancer Research</i> , 2011 , 17, 122-33	12.9	33
68	HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. <i>Clinical Cancer Research</i> , 2011 , 17, 5132-9	12.9	330

67 CHEMOTHERAPY FOR CASTRATION-RESISTANT PROSTATE CANCER 2011, 559-615

66	Tracing cancer networks with phosphoproteomics. <i>Nature Biotechnology</i> , 2010, 28, 1028-9	44.5	16
65	Somatic mutations of the Parkinson disease-associated gene PARK2 in glioblastoma and other human malignancies. <i>Nature Genetics</i> , 2010, 42, 77-82	36.3	280
64	Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4240-6	2.2	115
63	Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. <i>Clinical Cancer Research</i> , 2010, 16, 3329-34	12.9	138
62	PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. <i>Cancer Research</i> , 2010, 70, 6804-14	10.1	128
61	Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). <i>Cancer Research</i> , 2010, 70, 2264-73	10.1	185
60	The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 14903-8	11.5	383
59	Oncogenic RAF: a brief history of time. <i>Pigment Cell and Melanoma Research</i> , 2010, 23, 760-2	4.5	7
58	Genomic and biological characterization of exon 4 KRAS mutations in human cancer. <i>Cancer Research</i> , 2010, 70, 5901-11	10.1	218
57	4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. <i>Cancer Cell</i> , 2010, 18, 39-51	24.3	314
56	(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 4519-24	11.5	444
55	PIK3CA mutation associates with improved outcome in breast cancer. <i>Clinical Cancer Research</i> , 2009, 15, 5049-59	12.9	290
54	The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 9435-40	11.5	196
53	Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2436-42	2.2	79
52	Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. <i>Cancer Research</i> , 2009, 69, 4885-93	10.1	403
51	Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 264-70	2.2	49
50	Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo. <i>Nature Biotechnology</i> , 2008, 26, 91-100	44.5	94

49	Development and application of Hsp90 inhibitors. <i>Drug Discovery Today</i> , 2008 , 13, 38-43	8.8	229
48	Therapeutic strategies for inhibiting oncogenic BRAF signaling. <i>Current Opinion in Pharmacology</i> , 2008 , 8, 419-26	5.1	62
47	Genetic predictors of MEK dependence in non-small cell lung cancer. <i>Cancer Research</i> , 2008 , 68, 9375-83	10.1	216
46	Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. <i>Cancer Research</i> , 2008 , 68, 5524-8	10.1	185
45	SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. <i>Clinical Cancer Research</i> , 2008 , 14, 240-8	12.9	156
44	BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 2194-201	5.6	107
43	HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 3499-508	6.1	111
42	Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. <i>Cancer Research</i> , 2008 , 68, 589-96	10.1	155
41	Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. <i>Clinical Cancer Research</i> , 2008 , 14, 8302-7	12.9	179
40	The current state of preclinical prostate cancer animal models. <i>Prostate</i> , 2008 , 68, 629-39	4.2	103
39	A polyvalent vaccine for high-risk prostate patients: "are more antigens better?". <i>Cancer Immunology, Immunotherapy</i> , 2007 , 56, 1921-30	7.4	60
38	A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2007 , 59, 467-75	3.5	46
37	Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 1775-82	12.9	184
36	Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5410-7	2.2	288
35	³ Pdeoxy- ³ P[¹⁸ F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition. <i>Cancer Research</i> , 2007 , 67, 11463-9	10.1	63
34	Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. <i>PLoS ONE</i> , 2007 , 2, e810	3.7	93
33	Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2007 , 13, 2121-7	12.9	13
32	Therapeutic strategies for targeting BRAF in human cancer. <i>Reviews on Recent Clinical Trials</i> , 2007 , 2, 121-34	1.2	34

31	Hsp90: a novel target for cancer therapy. <i>Current Topics in Medicinal Chemistry</i> , 2006 , 6, 1205-14	3	146
30	Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors. <i>Cancer Research</i> , 2006 , 66, 6990-7	10.1	74
29	mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. <i>Cancer Research</i> , 2006 , 66, 1500-8	10.1	2114
28	BRAF mutation predicts sensitivity to MEK inhibition. <i>Nature</i> , 2006 , 439, 358-62	50.4	1137
27	Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. <i>Journal of Nuclear Medicine</i> , 2006 , 47, 793-6	8.9	125
26	The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. <i>Cancer Cell</i> , 2005 , 8, 287-97	24.3	348
25	Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. <i>Clinical Cancer Research</i> , 2005 , 11, 7454-61	12.9	112
24	Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. <i>Clinical Cancer Research</i> , 2005 , 11, 1983-9	12.9	114
23	Generation of DOTA-conjugated antibody fragments for radioimmunoimaging. <i>Methods in Enzymology</i> , 2004 , 386, 262-75	1.7	7
22	Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. <i>Nature Biotechnology</i> , 2004 , 22, 701-6	44.5	256
21	Hsp90: the vulnerable chaperone. <i>Drug Discovery Today</i> , 2004 , 9, 881-8	8.8	201
20	Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. <i>Chemistry and Biology</i> , 2004 , 11, 787-97		144
19	New efficient synthesis of resorcinyl macrolides via ynolides: establishment of cycloproparadicicol as synthetically feasible preclinical anticancer agent based on Hsp90 as the target. <i>Journal of the American Chemical Society</i> , 2004 , 126, 7881-9	16.4	152
18	Development of purine-scaffold small molecule inhibitors of Hsp90. <i>Current Cancer Drug Targets</i> , 2003 , 3, 371-6	2.8	98
17	Hsp90 as a therapeutic target in prostate cancer. <i>Seminars in Oncology</i> , 2003 , 30, 709-16	5.5	127
16	Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma. <i>Cancer</i> , 2003 , 98, 1842-8	6.4	32
15	Total Synthesis as a Resource in the Discovery of Potentially Valuable Antitumor Agents: Cycloproparadicicol. <i>Angewandte Chemie</i> , 2003 , 115, 1318-1322	3.6	11
14	Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 12337-42	11.5	78

13	Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. <i>Cancer Research</i> , 2003 , 63, 2139-44	10.1	184
12	Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3Pkinase/Akt pathway signaling. <i>Clinical Cancer Research</i> , 2003 , 9, 4340-6	12.9	180
11	Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids. <i>Cancer Research</i> , 2003 , 63, 8393-9	10.1	42
10	Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. <i>Oncogene</i> , 2002 , 21, 1159-66	9.2	226
9	Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. <i>Journal of Biological Chemistry</i> , 2002 , 277, 39858-66	5.4	479
8	17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. <i>Clinical Cancer Research</i> , 2002 , 8, 986-93	12.9	304
7	HER-Kinase-Directed Therapy of Prostate Cancer. <i>Prostate Journal</i> , 2001 , 3, 53-58		2
6	BRAF mutations in human cancer: biologic and therapeutic implications 272-277		
5	Enhanced specificity of high sensitivity somatic variant profiling in cell-free DNA via paired normal sequencing: design, validation, and clinical experience of the MSK-ACCESS liquid biopsy assay		2
4	Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2		2
3	Enhanced specificity of high sensitivity somatic variant profiling in cell-free DNA via paired normal sequencing: design, validation, and clinical experience of the MSK-ACCESS liquid biopsy assay		2
2	Anatomic position determines oncogenic specificity in melanoma		2
1	Oncologic therapy shapes the fitness landscape of clonal hematopoiesis		7